"Rilpivirine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone.
| Descriptor ID |
D000068696
|
| MeSH Number(s) |
D02.626.809 D03.383.742.755
|
| Concept/Terms |
TMC 278- TMC 278
- 278, TMC
- TMC278
- TMC-278
|
Below are MeSH descriptors whose meaning is more general than "Rilpivirine".
Below are MeSH descriptors whose meaning is more specific than "Rilpivirine".
This graph shows the total number of publications written about "Rilpivirine" by people in this website by year, and whether "Rilpivirine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 7 | 5 | 12 |
| 2018 | 9 | 0 | 9 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Rilpivirine" by people in Profiles.
-
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. J Infect Public Health. 2021 Oct; 14(10):1454-1460.
-
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. AIDS. 2020 01 01; 34(1):53-61.
-
Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019 07 01; 74(7):1992-2002.
-
Switch to rilpivirine improves diabetes in an elderly HIV-positive patient. Infez Med. 2019 Mar 01; 27(1):103-105.
-
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019 Apr; 53(4):515-519.
-
Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. J Int Assoc Provid AIDS Care. 2019 Jan-Dec; 18:2325958218821657.
-
Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev Anti Infect Ther. 2018 12; 16(12):877-887.
-
Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study. Antivir Ther. 2018; 23(7):629-632.
-
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
-
Dolutegravir-rilpivirine coformulation. Curr Opin HIV AIDS. 2018 07; 13(4):320-325.